Tumor-treating fields in glioblastoma: Indication of a benefit
Glioblastoma is an aggressive brain tumor that usually occurs in late adulthood. Just two years after diagnosis, only 13.6 percent …
Home ยป
MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market …